DRG Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in the emerging markets. We report the prevalence of PH for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of ten years for the pharmaceutical markets we cover in this report. In addition to forecasting prevalent patient populations, we forecast the number of drug-treatment opportunities in specific lines of therapy.

DRG Epidemiology’s PH forecast will answer the following questions:

  • How many people will be diagnosed with PH?
  • How will GDP trends, demographic trends, such as population aging and improving life expectancy, affect the epidemiology of PH over the forecast period?

Table of contents

  • Emerging Markets
    • Introduction
      • Prevalence of Pulmonary Hypertension per 1,000 Among People of All Ages in 2018 and 2028
      • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Pulmonary Hypertension over the Next Ten Years
      • Number of Additional Prevalent Cases of Pulmonary Hypertension in 2028 Across the Countries Under Study Due to Trends in Risk or Survival
    • Epidemiology Data
    • Methods
      • Diagnosed Prevalent Cases of Pulmonary Arterial Hypertension
      • Diagnosed Prevalent Cases of Pulmonary Arterial Hypertension by Functional Class
      • Diagnosed Prevalent Cases of Pulmonary Hypertension due to Left Heart Disease
      • Diagnosed Prevalent Cases of Pulmonary Hypertension due to Lung Disease
      • Diagnosed Prevalent Cases of Chronic Thromboembolic Pulmonary Hypertension
      • Diagnosed Prevalent Cases of Chronic Thromboembolic Pulmonary Hypertension by Operability
      • Diagnosed Prevalent Cases of Pulmonary Hypertension due to Miscellaneous Causes
      • Diagnosed Prevalent Cases of Pulmonary Hypertension (All Causes)
      • Drug-Treated Cases of Pulmonary Arterial Hypertension
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Dr. Ravdeep Kaur, MPH; Alison Isherwood, MSc, MRes, PhD

Ravdeep Kaur started working in Decision Resources Inc. as an associate epidemiologist since December 31 st , 2015. She performs fully documented systematic reviews of both published and grey literature on the epidemiology of assigned diseases and their risk factors to estimate incidence/prevalence over a 10-30 year period. She produces analyses for pharmaceutical drug developers on the descriptive epidemiology of major drug indications in mature and developing markets. She holds a Master’s in Public Health degree from School of Public Health, Post-Graduate Institute of Medical Education and Research and a Bachelor’s in dental surgery from Rajiv Gandhi University of Health Sciences, India. She also has a Fellowship in Heath care Technology Assessment from World health Organization (WHO), India office.  Prior to joining Decision Resources, Ravdeep worked as a Consultant in Reproductive, Maternal, Child and Adolescent Health Program in a United States Agency for International development (USAID) funded project.   

Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.


Related Reports

Pulmonary Hypertension | Epidemiology | Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key pulmonary hypertension pat...

View Details

Pulmonary Hypertension | Landscape & Forecast | Disease Landscape & Forecast

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the disease’s rarity, the p...

View Details

Hypertension | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

Primary, or essential, hypertension is defined as persistently elevated blood pressure (BP) without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., co...

View Details

Pulmonary Hypertension | Current Treatment | Detailed, Expanded Analysis (US)

Pulmonary hypertension (PH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Off-label drug use is widespread, with approved drugs available only for the tr...

View Details